19:17:31 EDT Sun 07 Aug 2022
Enter Symbol
or Name
USA
CA



Login ID:
Password:
Save
Avicanna Inc
Symbol AVCN
Shares Issued 45,858,596
Close 2022-01-04 C$ 0.76
Recent Sedar Documents

Avicanna names McCormack as director; Purohit resigns

2022-01-04 09:12 ET - News Release

Mr. Aras Azadian reports

AVICANNA ANNOUNCES CHANGES TO ITS BOARD OF DIRECTORS

Avicanna Inc. has appointed Eileen McCormack to its board of directors, effective immediately, and Setu Purohit has resigned as a director.

Ms. McCormack is an experienced senior marketing executive with more than 30 years of international experience in the biopharmaceutical industry. Ms. McCormack retired from AstraZeneca U.S. where she led commercial and cross-functional teams responsible for launch planning and business development in the United States market. Ms. McCormack has experience in biopharmaceutical product development, portfolio strategy in complex regulated environments, and brings significant multimarket and international commercial experience. Ms. McCormack gives back to her community by having served on a number of national and Toronto-based not-for-profit boards over the last 10 years.

"I am excited to be joining the Avicanna board of directors," said Ms. McCormack. "I believe Avicanna has a strong business model and talented management team that uniquely positions it to capitalize on the evolving cannabinoid-based biopharmaceutical industry. I look forward to contributing to Avicanna's future growth and success as the company executes development and launch activities for its evidence-based products."

"We are pleased to add Ms. McCormack to our board of directors at an appropriate time where her experience and wisdom can support the next phase of evolution of the company, including pipeline analysis and global commercialization efforts," stated Aras Azadian, chief executive officer of Avicanna.

About Avicanna Inc.

Avicanna is a Canadian commercial-stage biopharmaceutical company established in cannabinoid research, development and evidence-based products for the global consumer, as well as medical and pharmaceutical market segments. In leading global cannabinoid advancements, Avicanna conducts most of its research in Canada at its research and development headquarters in the Johnson & Johnson Innovation Centre, JLABS @ Toronto, located in the MaRS discovery district. The company actively collaborates with leading Canadian academic and medical institutions. Avicanna has established an industry-leading scientific platform, including advanced research and development and clinical development, which has led to the commercialization of over 20 products across four main market segments.

We seek Safe Harbor.

© 2022 Canjex Publishing Ltd. All rights reserved.